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IntroductIon
Rapid sequence induction (RSI) is a medical procedure involving the prompt induction of general anesthesia and subsequent laryngoscopy and endotracheal intubation. It is typically used in an emergency setting for patients at the risk of regurgitation/aspiration or raised intracranial pressure (ICP). Laryngoscopy and intubation performed during RSI lead to choroidal blood volume increase and an eventual rise in intraocular pressure (IOP). [1] Physiologic mechanisms maintain normal IOP between 11 and 21 mm Hg. Pressure must be maintained within this range to ensure constant corneal curvature and a proper refracting index of the eye. [2] Values higher than 25 mm Hg are considered to be pathologic and in case of a perforated globe could lead to the expulsion of intraocular contents. [3] Both depolarizing and nondepolarizing muscle relaxants have been used for RSI. Nondepolarizing muscle relaxants when used for this purpose are required in very high doses leading to unnecessary prolongation of duration of action. Among depolarizing muscle relaxants, succinylcholine (SCh) is the drug of choice for RSI. [4] It is preferred in RSI because it has the fastest onset and shortest duration of action among all muscle relaxants. The former is a major point of consideration in the context of trauma care, where endotracheal intubation may need to be accomplished early. The latter means that, if attempts at endotracheal intubation fail and the patient cannot be ventilated, there is a prospect for neuromuscular recovery and the onset of spontaneous breathing before hypoxemia occurs. The use of SCh, however, causes an undesirable rise in IOP which is further aggravated by laryngoscopy and endotracheal intubation. [4] This may prove hazardous in patients with penetrating eye injuries and patients with preexisting high IOP. [5] The mechanism of rise in IOP due to SCh is thought to be caused by the contraction of extraocular muscles although dilatation of choroidal vessels is a contributory factor. [6] Various methods have been used to attenuate the effects of SCh on IOP; they include self-taming with 1/10 th dose of SCh, [7] pretreatment with nondepolarizing muscle relaxant [8] and the use of 300 µg per oral clonidine. [9] However, no modality has been devoid of drawbacks and limitations. With α 2 receptor agonists, vasoconstrictor effects have been observed in several vascular beds, including the eye. [10] Dexmedetomidine is a highly selective centrally acting α 2 adrenergic agonist that has IOP lowering properties. [11] It exerts its effects by binding to α 2 receptors pre-and postsynaptically in the locus ceruleus (a cluster of nerves that lies near the 4 th ventricle of brain) and in the spinal cord. [12] The purpose of the present study is to evaluate the role of dexmedetomidine at a selective dose of 0.5 µg/kg for attenuation of the increase in IOP due to RSI using SCh.
subjects and methods
The study was carried out in the Department of Anaesthesiology of a tertiary care teaching hospital after obtaining the clearance from Institutional Ethical Committee. This study incorporated sixty adult patients in the age group of 20-50 years scheduled for elective surgeries under general anesthesia. All patients were examined for depth of anterior chamber and fundus of the right eye by an ophthalmologist. After assessing the patients for anesthesia, informed consent of patients for the proposed study, and anesthesia was obtained. Patients were kept fasting overnight, and no premedication was given. On arrival of patients in the operation theater, intravenous (i.v.) line was initiated with 18G cannula. Preoperative recording of heart rate (HR), noninvasive blood pressure, and arterial oxygen saturation (SpO 2 ) were made.
Preoperative baseline IOP was measured with a Schiotz tonometer after installation of 4% lignocaine drops in the right eye by an ophthalmologist.
The patients were randomly allocated into two groups of thirty each:
• Group I (dexmedetomidine group) (n = 30) received i.v. infusion of dexmedetomidine (0.5 µg/kg) diluted in normal saline to make a solution of 50 ml as premedication, over a period of 10 min • Group II (control group) (n = 30) received i.v. infusion of 50 ml normal saline as premedication, over a period of 10 min.
Standard anesthetic techniques were followed. All patients were preoxygenated with 100% oxygen for 3 min. Induction of anesthesia was carried out with injection propofol 1% 2 mg/kg intravenously. SCh was administered at a dose of 2 mg/kg to achieve muscular relaxation for intubation in both groups. After cessation of fasciculations, the trachea was intubated under direct vision laryngoscopy. Those patients who could not be intubated in the first attempt were excluded from the study. After securing the airway, anesthesia was maintained in both groups with oxygen (33.33%), nitrous oxide (66.67%), halothane (0.4%-1.2%), and intraoperative relaxation was maintained by rocuronium in a dose of 0.6 mg/kg bolus followed by incremental doses of 0.12 mg/kg. Out of sixty patients enrolled in the study, only 22 (36.67%) were females. The proportion of females was higher in Group I (40.00%) as compared to Group II (33.33%), but this difference was not found to be statistically significant (P = 0.592) [ Table 2 ].
At baseline, all the above variables except SpO 2 in Group II were found to be higher than that of Group I, but differences were not found to be statistically significant.
SpO 2 levels of Group I and Group II were found to be similar with each other, and no difference was found between them [ Table 3 ].
At baseline (T1), HR of Group I (73.37 ± 5.44 per min) was found to be lower than that of Group II (74.00 ± 4.50 per min) but difference in HR of both the groups was not found to be statistically significant (P = 0.625).
At all the time periods from T1 to T8 HR of Group II patients were found to be higher than that of Group I patients except at period T7 where HR of Group I (75.83 ± 5.08 per min) was found to be higher than that of Group II (75.03 ± 4.51 per min). Difference in HR of both groups was found to be statistically significant (P < 0.001) at all time intervals except at T1 (P = 0.625), T7 (P = 0.521), and T8 (P = 0.126) [ Table 4 ].
At baseline (T1), MAP of Group I (92.00 ± 5.91 mm Hg) was found to be lower than that of Group II (93.03 ± 5.43 mm Hg), but the difference in MAP of both the groups was not found to be statistically significant (P = 0.483).
At all the other time intervals from T2 to T8 MAP of Group II was found to be higher than that of Group I and difference at each of the time interval was found to be statistically significant (P < 0.001) [ Table 5 ].
At baseline (T1), IOP of the right eye of Group I (12.90 ± 1.94 mm Hg) was found to be lower than that of Group II (13.08 ± 1.91 mm Hg), and this difference was not found to be statistically significant.
At all other time intervals from T2 to T8, IOP of the right eye of Group I was found to be lower than that of Group II. The difference in IOP of right eye of both the groups was found to be statistically significant at T2 to T6 (P < 0.001) and statistically nonsignificant at T7 (P = 0.233) and T8 (P = 0.757) [ Table 6 and Figure 1 ]. In Group I, at T2 a decline in HR (2.13 ± 0.57 per min) from its baseline value (T1) was observed, this change in HR from its baseline value was found to be statistically significant. Thereafter, between time intervals T3 to T7 HR were found to be above the baseline value and change in HR at all these time intervals was found to be statistically significant (P < 0.001). At T8, HR was found to be lower than that at baseline (2.80 ± 2.12 per min), and this change from its baseline value was found to be statistically significant (P < 0.001). Maximum change in HR from its baseline value was found at T5 (7.60 ± 1.69 
In Group II, HR at all time intervals except at T8 were found to be higher than its value at T1 (baseline), and at T8 time interval, the HR was found to be lower than its baseline value (T1). The maximum change was observed at T5 (19.17 ± 1.74 per min), and change was found to be minimum at T7 (1.03 ± 2.66 per min). Change in HR from its baseline value was found to be statistically significant at all the above time intervals [ Table 7 ].
In Group I, at all time intervals, MAP was found to be lower than its value at Time T1. Minimum change in MAP was observed at T2 (7.07 ± 0.91 mm Hg), and maximum change was observed at T7 (22.00 ± 2.77 mm Hg). Change in MAP from its baseline value was found to be statistically significant at all time intervals.
In Group II, MAP was found to be higher than its value at baseline (T1) at time intervals between T2 and T5 and was found to be lower than its baseline value at time intervals T6, T7, and T8. Minimum change in MAP was found at T3 (0.10 ± 1.06 mm Hg), and maximum change was observed at T7 (12.97 ± 4.90 mm Hg). Change in MAP from its baseline value was found to be statistically significant at all time intervals except at T3 (P = 0.610) [ Table 8 ].
In Group I, at all the time intervals, IOP of the right eye remained lower than its baseline value (T1). Maximum change from its baseline value was observed at T7 (4.16 ± 1.74 mm Hg), and minimum change was observed at T5 (0.26 ± 1.78 mm Hg). Change in IOP was found to be statistically significant at all time intervals except at T4 and T5.
In Group II, IOP of the right eye was found to be lower than its baseline (T1) value at time intervals at T2, T3, T6, T7, and T8 while it was found to be higher than its baseline value at T4 and T5 time intervals. Minimum change from its baseline value was found at T2 (0.67 ± 0.60 mm Hg), and maximum change was observed at T5 (4.81 ± 1.68 mm Hg). Change in IOP of the right eye was found to be statistically significant at all the time intervals [ Table 9 and Figure 2] .
dIscussIon
RSI is a process whereby pharmacological agents, specifically a sedative (e.g., induction agent) and a neuromuscular blocking agent, are administered in rapid succession to facilitate endotracheal intubation. [13] The purpose of RSI is to make emergent intubation easier and safer, thereby increasing the success rate and decreasing the complications of intubation. The rationale behind RSI is to prevent aspiration and its potential problems including aspiration pneumonia and to counteract the increase in systemic arterial blood pressure, HR, plasma catecholamine release, ICP, and IOP that occur with endotracheal intubation. Avoiding an increase in IOP may be desirable, especially in the patients with glaucoma or acute eye injury. [14] SCh, the only depolarizing neuromuscular blocking agent currently available, has been used in innumerable patients since its introduction as a neuromuscular blocking drug (NMBD) in 1952. It is the most commonly used NMBD for RSI. [15, 16] SCh is the prototype of the depolarizing agents. Since its chemical structure (i.e., quaternary ammonium compound) is similar to that of acetylcholine (ACh), it binds to the ACh receptors (AChRs) on the motor end plate and depolarizes the postjunctional neuromuscular membrane, resulting in continuous stimulation of the motor end plate AChRs. The major advantages of Sch are its rapid onset with complete motor paralysis occurring within 45-60 s and short duration of action lasting only 6-10 min when given in the recommended 1.5-mg/kg i.v. dose. Despite its rapid onset, SCh has several side effects such as hyperkalemia, bradycardia, prolonged neuromuscular blockade, increased ICP, increased IOP, trismus, fasciculations, and malignant hyperthermia, which limit its use in RSI. It has been reported that SCh increases the IOP by 6-8 mm Hg. Various methods have been used to attenuate the effects of SCh on IOP. They included self-taming, where a 1/10 th dose of SCh is given initially followed by the remaining amount of SCh and pretreatment with nondepolarizing neuromuscular blocking agents, lidocaine, opioids, nifedipine, or nitroglycerin. [17] However, no modality was devoid of drawbacks and limitations. Rocuronium, an intermediate-acting nondepolarizing muscle relaxant used commonly, provides good intubating condition after 60-90s, but it is not preferred in patients with anticipated difficult airway. [18, 19] Dexmedetomidine is a highly selective α 2 -adrenergic agonist that has sedative and analgesic effects. [14] α 2 -adrenergic agonists provide potentially beneficial effects in ophthalmic surgery because of their IOP-lowering properties. [14, 20] Recent studies have shown its successful use for attenuation of suxamethonium and SCh-induced IOP among patients undergoing rapid sequence intubation. [5, 11, 14, 20] However, some authors have expressed reservations on the use of dexmedetomidine owing to its hemodynamic effect. [11] Hence, the present study was carried out with an aim to evaluate the efficacy of i.v. infusion of dexmedetomidine premedication with 0.5 µg/kg in attenuating the rise of IOP caused by SCh in patients undergoing RSI for general anesthesia and to monitor and manage the side effects of dexmedetomidine.
For this purpose, a total of sixty adult patients in the age group of 20-50 years scheduled for elective surgeries under general anesthesia were enrolled in the study and were randomly allocated to one of the two groups -Group I included thirty patients who were given i.v. infusion of dexmedetomidine (0.5 µg/kg) diluted in normal saline to make a solution of 50 ml as premedication, over a period of 10 min and comprised the study group whereas the remaining 30 patients were given i.v. infusion of 50 ml normal saline as premedication, over a period of 10 min and comprised the control group of the study.
At baseline, both groups had matched mean values with mean IOP right eye of Group I being 12.90 ± 1.94 mm Hg as compared to 13.08 ± 1.91 mm Hg in Group II (P > 0.05).
At all the other time intervals from T2 to T8, IOP of the right eye of Group I was found to be lower than that of Group II. The difference in IOP of right eye of both the groups was found to be statistically significant at T2 to T6 (P < 0.001) and statistically nonsignificant at T7 (P = 0.233) and T8 (P = 0.757).
With respect to change in IOP, in study group just after the conclusion of premedication, a decrease (−2.83 ± 0.65 mm Hg) in mean IOP was observed. Thirty seconds after the induction of anesthesia the decline reached to −3.58 ± 0.93 mm of Hg. Thirty seconds after SCh injection a slight increase in IOP was observed taking the difference to −0.52 ± 1.63 mm of Hg. Immediately after intubation, another increase in IOP was observed which led to take the gap from baseline to be −0.26 ± 1.78 mm of Hg. However, at 2 min and 4 min, postintubation intervals a declining trend of IOP was observed followed by a slight incline at 6 min. At 6 min postintubation interval, mean IOP was lower than baseline value by −4.03 ± 1.63 mm of Hg. At all the time intervals except 30 s post SCh injection and postintubation intervals, the difference from baseline was significant statistically (P < 0.001).
In control group, premedication a decrease (−0.67 ± 0.60 mm Hg) in mean IOP was observed. Thirty seconds after induction of anesthesia, the decline reached to −2.67 ± 0.77 mm of Hg. Thirty seconds after SCh injection a slight increase in IOP was observed taking the difference to 2.87 ± 1.81 mm of Hg. Immediately after intubation, another increase in IOP was observed which took the gap from baseline to 4.81 ± 1.68 mm of Hg. However, at 2 min postintubation interval onward a declining trend of IOP was observed. At 6 min postintubation interval, mean IOP was lower than baseline value by 4.06 ± 1.64 mm of Hg. At all the time intervals, the difference from baseline was significant statistically (P < 0.001).
On comparing the mean IOP levels in the two groups, at all time intervals except at baseline, 4 and 6 min postintubation intervals, mean IOP was significantly higher in control group as compared to the dexmedetomidine group.
The study findings showed that at all the time intervals dexmedetomidine had a better control on mean IOP. α-adrenergic blockers such as dexmedetomidine and clonidine have shown a good attenuating effect on IOP following SCh and suxamethonium use. [9, 14, 20] For IOP trends similar to the present study were also obtained by Pal et al., [5] who reported the use of 0.4 µg/kg and 0.6 µg/kg dexmedetomidine infusion and found the comparable results for control of IOP following the use of suxamethonium as the muscle relaxant and rapid sequence intubation, for both the dosages and obtained significantly lower mean values in both groups as compared to control group. Mowafi et al. [11] in their study using 0.6 µg/kg dexmedetomidine found results exactly comparable to results in the present study. In the present study, maximum postintubation increase in IOP was nearly 36% in control group as compared to −2% decline at the same time in dexmedetomidine group, thus showing the difference between two groups to be almost 38%.
The intraocular hypotensive effect of dexmedetomidine in the present study is consistent with the previous several researches on α 2 -adrenergic agonists. Clonidine was effective in preventing the rise of the IOP in response to SCh and endotracheal intubation. [9, 21, 22] Similar effects were shown in elderly patients during cataract surgery. [23, 24] Only two studies till date have examined the effect of dexmedetomidine on the SCh-induced ocular hypertension. [11] According to explanation given by Mowafi et al., [11] the effect of dexmedetomidine on the IOP may be caused by a direct vasoconstrictor effect on the afferent blood vessels of the ciliary body, which results in reduction of aqueous humor production. [25] Moreover, it could increase outflow of the aqueous humor caused by a reduction of the sympathetically mediated vasomotor tone of the ocular drainage system. [26] In addition, its associated hemodynamic response could contribute to the IOP lowering effect. [27] The study findings showed that at all the time intervals dexmedetomidine had a better control on HR. Dexmedetomidine is an α 2 -adrenoceptor, presynaptic activation of the α 2 -adrenoreceptors inhibits the release of norepinephrine, terminating the propagation of pain signals. Postsynaptic activation of α 2 -adrenoreceptors in the central nervous system inhibits sympathetic activity and thus can decrease blood pressure and HR. [17] For HR trends, similar to the present study were also obtained by Pal et al., [5] who reported the use of 0.4 µg/kg and 0.6 µg/kg dexmedetomidine infusion and found the comparable results for control of HR following the use of suxamethonium as the muscle relaxant, for both the dosages and obtained significantly lower mean values in both the groups as compared to control group. Mowafi et al. [11] in their study using 0.6 µg/kg dexmedetomidine found results exactly comparable to results in the present study. In the present study, maximum postintubation increase in HR was 10% lower in dexmedetomidine group as compared to control group. The study findings showed that at all the time intervals, dexmedetomidine had a better control on MAP. Dexmedetomidine has a known blood pressure-lowering effect. It is a fast-acting blood pressure attenuating agent and has been shown to be quite successful in attenuation of hemodynamic reflex in endotracheal intubation and laryngoscopy for different procedures [28] [29] [30] [31] and has been shown to have comparable or better attenuating effect on pressor response as compared to a number of anesthetic drugs, namely, lidocaine, esmolol etc., at variable dosages ranging from 0.4 µg/kg to 1.0 µg/kg. For MAP trends similar to the present study were also obtained by Pal et al., [5] who reported the use of 0.4 µg/kg and 0.6 µg/kg dexmedetomidine infusion and found the comparable results for control of MAP following the use of suxamethonium as the muscle relaxant and rapid sequence intubation for both the dosages and obtained significantly lower mean values in both the groups as compared to control group.
Dexmedetomidine is known to have a hypotensive effect. [19] However, in the present study, no such effect was observed. In none of the patients, any withdrawal from the study owing to hypotensive effect of dexmedetomidine was observed. Contrary to our observations, Pal et al. [5] reported hypotension in two patients to be the reason for their withdrawal from the study. This finding could only be incidental as even higher dosages of dexmedetomidine when used to attenuate hemodynamic reflex following endotracheal intubation did not result in any such hypotensive effect leading to withdrawal from study.
A limitation of this study was that the effect of dexmedetomidine on the IOP changes after SCh and intubation could not be isolated from its action on the hemodynamics since both effects are parallel and a causal relationship cannot be denied. However, this limitation should not decline the potential advantage of using dexmedetomidine as an alternative agent to obtund the IOP changes of SCh and intubation.
Hence, it can be concluded that the rise of IOP with SCh and rapid sequence intubation can be blunted with i.v. dexmedetomidine premedication. The hemodynamic stability is an additional advantage. Further studies are recommended to corroborate the findings.
conclusIon
The findings in the present study indicate that i.v. dexmedetomidine effectively attenuates the increases in IOP with an additional advantage of control on hemodynamic responses following RSI. Hence, dexmedetomidine can safely be recommended as i.v. premedication for attenuation of rise in IOP.
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